Zacks Investment Research lowered shares of Kura Oncology, Inc. (NASDAQ:KURA) from a buy rating to a hold rating in a report published on Thursday.

According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “

KURA has been the subject of a number of other reports. ValuEngine cut shares of Kura Oncology from a hold rating to a sell rating in a research report on Friday, September 1st. Oppenheimer Holdings, Inc. reiterated a buy rating and set a $16.00 price objective on shares of Kura Oncology in a research report on Tuesday, July 4th. Leerink Swann reiterated an outperform rating and set a $18.00 price objective (up from $16.00) on shares of Kura Oncology in a research report on Thursday, August 10th. Cowen and Company began coverage on shares of Kura Oncology in a research report on Thursday, September 7th. They set an outperform rating for the company. Finally, Citigroup Inc. set a $13.00 price objective on shares of Kura Oncology and gave the stock a buy rating in a research report on Tuesday, August 8th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Kura Oncology presently has an average rating of Buy and a consensus target price of $15.60.

Shares of Kura Oncology (NASDAQ KURA) opened at 12.95 on Thursday. Kura Oncology has a one year low of $4.00 and a one year high of $13.80. The firm’s market cap is $258.84 million. The company has a 50 day moving average of $8.37 and a 200-day moving average of $8.90.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Monday, August 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.43) by $0.03. On average, analysts expect that Kura Oncology will post ($1.53) EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Kura Oncology, Inc. (KURA) Downgraded by Zacks Investment Research” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this article can be read at https://www.thecerbatgem.com/2017/09/18/kura-oncology-inc-kura-downgraded-by-zacks-investment-research.html.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Goldman Sachs Group Inc. acquired a new position in Kura Oncology in the 1st quarter valued at approximately $533,000. Renaissance Technologies LLC increased its position in Kura Oncology by 158.8% in the 1st quarter. Renaissance Technologies LLC now owns 79,200 shares of the company’s stock valued at $697,000 after acquiring an additional 48,600 shares during the period. Alethea Capital Management LLC increased its position in Kura Oncology by 128.1% in the 2nd quarter. Alethea Capital Management LLC now owns 193,346 shares of the company’s stock valued at $1,798,000 after acquiring an additional 108,577 shares during the period. Nationwide Fund Advisors acquired a new position in Kura Oncology in the 1st quarter valued at approximately $136,000. Finally, Segantii Capital Management Ltd acquired a new position in Kura Oncology in the 1st quarter valued at approximately $120,000. Hedge funds and other institutional investors own 39.07% of the company’s stock.

Kura Oncology Company Profile

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Get a free copy of the Zacks research report on Kura Oncology (KURA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Stock Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related stocks with our FREE daily email newsletter.